142 related articles for article (PubMed ID: 11517933)
21. A role for cathepsin L and cathepsin S in peptide generation for MHC class II presentation.
Hsieh CS; deRoos P; Honey K; Beers C; Rudensky AY
J Immunol; 2002 Mar; 168(6):2618-25. PubMed ID: 11884425
[TBL] [Abstract][Full Text] [Related]
22. Both cathepsin B and cathepsin D are necessary for processing of ovalbumin as well as for degradation of class II MHC invariant chain.
Mizuochi T; Yee ST; Kasai M; Kakiuchi T; Muno D; Kominami E
Immunol Lett; 1994 Dec; 43(3):189-93. PubMed ID: 7721331
[TBL] [Abstract][Full Text] [Related]
23. Anti-cathepsin L monoclonal antibodies that distinguish cathepsin L from cathepsin V.
Kopitar-Jerala N; Bevec T; Barlic-Maganja D; Gubensek F; Turk V
Biol Chem; 2001 May; 382(5):867-70. PubMed ID: 11517943
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and NMR structure of p41icf, a potent inhibitor of human cathepsin L.
Chiva C; Barthe P; Codina A; Gairí M; Molina F; Granier C; Pugnière M; Inui T; Nishio H; Nishiuchi Y; Kimura T; Sakakibara S; Albericio F; Giralt E
J Am Chem Soc; 2003 Feb; 125(6):1508-17. PubMed ID: 12568610
[TBL] [Abstract][Full Text] [Related]
25. Improvement of cathepsin S detection using a designed FRET peptide based on putative natural substrates.
Oliveira M; Torquato RJ; Alves MF; Juliano MA; Brömme D; Barros NM; Carmona AK
Peptides; 2010 Apr; 31(4):562-7. PubMed ID: 20045715
[TBL] [Abstract][Full Text] [Related]
26. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice.
Nakagawa TY; Brissette WH; Lira PD; Griffiths RJ; Petrushova N; Stock J; McNeish JD; Eastman SE; Howard ED; Clarke SR; Rosloniec EF; Elliott EA; Rudensky AY
Immunity; 1999 Feb; 10(2):207-17. PubMed ID: 10072073
[TBL] [Abstract][Full Text] [Related]
27. Identification and characterization of major histocompatibility complex class II compartments in cortical thymic epithelial cells.
Arudchelvan Y; Nishimura Y; Tokuda N; Sawada T; Ueyama Y; Fukumoto T
Anat Rec A Discov Mol Cell Evol Biol; 2003 Sep; 274(1):798-806. PubMed ID: 12923890
[TBL] [Abstract][Full Text] [Related]
28. Cathepsin S activity regulates antigen presentation and immunity.
Riese RJ; Mitchell RN; Villadangos JA; Shi GP; Palmer JT; Karp ER; De Sanctis GT; Ploegh HL; Chapman HA
J Clin Invest; 1998 Jun; 101(11):2351-63. PubMed ID: 9616206
[TBL] [Abstract][Full Text] [Related]
29. Thyroglobulin type-I-like domains in invariant chain fusion proteins mediate resistance to cathepsin L digestion.
Hitzel C; Kanzler H; König A; Kummer MP; Brix K; Herzog V; Koch N
FEBS Lett; 2000 Nov; 485(1):67-70. PubMed ID: 11086167
[TBL] [Abstract][Full Text] [Related]
30. The p41 fragment story.
Turk D; Guncar G; Turk V
IUBMB Life; 1999 Jul; 48(1):7-12. PubMed ID: 10791909
[TBL] [Abstract][Full Text] [Related]
31. Proteases involved in MHC class II antigen presentation.
Villadangos JA; Bryant RA; Deussing J; Driessen C; Lennon-Duménil AM; Riese RJ; Roth W; Saftig P; Shi GP; Chapman HA; Peters C; Ploegh HL
Immunol Rev; 1999 Dec; 172():109-20. PubMed ID: 10631941
[TBL] [Abstract][Full Text] [Related]
32. Expression of invariant chain and pro-cathepsin L in Alzheimer's brain.
Yoshiyama Y; Arai K; Oki T; Hattori T
Neurosci Lett; 2000 Aug; 290(2):125-8. PubMed ID: 10936693
[TBL] [Abstract][Full Text] [Related]
33. Degradation of mouse invariant chain: roles of cathepsins S and D and the influence of major histocompatibility complex polymorphism.
Villadangos JA; Riese RJ; Peters C; Chapman HA; Ploegh HL
J Exp Med; 1997 Aug; 186(4):549-60. PubMed ID: 9254653
[TBL] [Abstract][Full Text] [Related]
34. Immunocompetent astrocytes and microglia display major differences in the processing of the invariant chain and in the expression of active cathepsin L and cathepsin S.
Gresser O; Weber E; Hellwig A; Riese S; Régnier-Vigouroux A
Eur J Immunol; 2001 Jun; 31(6):1813-24. PubMed ID: 11433378
[TBL] [Abstract][Full Text] [Related]
35. Developmental regulation of invariant chain proteolysis controls MHC class II trafficking in mouse dendritic cells.
Pierre P; Mellman I
Cell; 1998 Jun; 93(7):1135-45. PubMed ID: 9657147
[TBL] [Abstract][Full Text] [Related]
36. Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity.
Saegusa K; Ishimaru N; Yanagi K; Arakaki R; Ogawa K; Saito I; Katunuma N; Hayashi Y
J Clin Invest; 2002 Aug; 110(3):361-9. PubMed ID: 12163455
[TBL] [Abstract][Full Text] [Related]
37. Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading.
Riese RJ; Wolf PR; Brömme D; Natkin LR; Villadangos JA; Ploegh HL; Chapman HA
Immunity; 1996 Apr; 4(4):357-66. PubMed ID: 8612130
[TBL] [Abstract][Full Text] [Related]
38. Differential regulation of cathepsin S and cathepsin L in interferon gamma-treated macrophages.
Beers C; Honey K; Fink S; Forbush K; Rudensky A
J Exp Med; 2003 Jan; 197(2):169-79. PubMed ID: 12538657
[TBL] [Abstract][Full Text] [Related]
39. Expression of cathepsins B, L, S, and D by gastric epithelial cells implicates them as antigen presenting cells in local immune responses.
Barrera C; Ye G; Espejo R; Gunasena S; Almanza R; Leary J; Crowe S; Ernst P; Reyes VE
Hum Immunol; 2001 Oct; 62(10):1081-91. PubMed ID: 11600214
[TBL] [Abstract][Full Text] [Related]
40. Invariant chain p41 mediates production of soluble MHC class II molecules.
Shishido T; Kohyama M; Nakai W; Matsumoto M; Miyata H; Suenaga T; Arase H
Biochem Biophys Res Commun; 2019 Jan; 509(1):216-221. PubMed ID: 30587340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
